Cited by 2,056Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseasesTransplantation: Methods and Outcomes

The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.

Idiopathic Pulmonary Fibrosis

Lederer, David J., Martinez, Fernando J.·2018·New England Journal of Medicine

DOI 10.1056/nejmra1705751

Open this paper in CoChat — free account

Abstract

Idiopathic pulmonary fibrosis appears to be increasing in incidence. It requires early recognition and intervention with supportive care and pharmacologic agents to forestall its progression. Lung transplantation may be curative.

Integrity signals

Registry

Crossref · 10.1056/nejmra1705751

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Self-citation
Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2013) · Annals of Internal Medicine · doi:10.7326/m13-2771 · Cited by 2,642
Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017.
MacMahon, H., Naidich, D. P., Goo, J. M., Lee, K. S., Leung, A. N. C., Mayo, J. R., Mehta, A. C., Ohno, Y., Powell, C. A., Prokop, M., et al. (2017) · Radiology · doi:10.1148/radiol.2017161659 · Cited by 2,491
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice Guideline
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Prednisone, Azathioprine, and N -Acetylcysteine for Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113354 · Cited by 1,654
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444
Self-citation
Telomerase Mutations in Families with Idiopathic Pulmonary Fibrosis
Armanios, M. Y., Chen, J. J.-L., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M., Vulto, I., Phillips, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066157 · Cited by 1,357
A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation
Weill, D., Benden, C., Corris, P. A., Dark, J. H., Davis, R. D., Keshavjee, S., Lederer, D. J., Mulligan, M. J., Patterson, G. A., Singer, L. G., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.06.014 · Cited by 1,329
Self-citation

Show all 98 references

Research works printed but not linked: 2

Philp CJ, Siebeke I, Clements D, et al. ECM crosslinking enhances fibroblast growth and protects against matrix proteolysis in lung fibrosis. Am J Respir Cell Mol Biol 2017 October 20 (Epub ahead of print).29053339
Parker J, Sawtell R, Gagnon L, et al. PBI-4050 is safe and well tolerated and shows evidence of benefit in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2017;195:A7606-A7606. abstract.

Sorted by citations

Items 401–500 of 1,001

Fullerene‐Based Immunoregulatory Nanomaterials for Immunotherapy of Tumor and Immune‐Related Inflammatory Diseases
Zhen, M., Xu, Y. M., Wang, C., & Bai, C. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202409319 · Cited by 36
Why Does an Aging Smoker’s Lung Develop Idiopathic Pulmonary Fibrosis and Not Chronic Obstructive Pulmonary Disease?
Selman, M., Martínez, F. J., & Pardo, A. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201806-1166pp · Cited by 37
Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis
Nathan, S. D., Mehta, J., Stauffer, J. L., Morgenthien, E. A., Yang, M., Limb, S. L., & Bhorade, S. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071427 · Cited by 33
Ferroptosis-Related Genes in Bronchoalveolar Lavage Fluid Serves as Prognostic Biomarkers for Idiopathic Pulmonary Fibrosis
Li, M., Wang, K., Zhang, Y., Fan, M., Li, A., Zhou, J., Yang, T., Shi, P., Li, D., Zhang, G., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.693959 · Cited by 36
“Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, age-related interstitial pulmonary disease (ILD) with unknown etiology, significant morbidity, and unfavorable survival (1, 2).”
Background
Delivery of sorafenib by myofibroblast-targeted nanoparticles for the treatment of renal fibrosis
Cheng, H., Huang, H., Lee, T., Liao, Y., Sheng, Y.-H., Jin, P.-R., Huang, K., Chen, L.-H., Chen, Y., Lin, T., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.004 · Cited by 34
IL‐17A promotes lung fibrosis through impairing mitochondrial homeostasis in type II alveolar epithelial cells
Xiao, H., Peng, L., Jiang, D., Liu, Y., Zhu, L., Li, Z., Geng, J., Xie, B., Huang, X., Wang, J., et al. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17600 · Cited by 35
Use of Chou’s 5-Steps Rule to Reveal Active Compound and Mechanism of Shuangshen Pingfei San on Idiopathic Pulmonary Fibrosis
Chen, Y., & Fan, X. (2019) · Current Molecular Medicine · doi:10.2174/1566524019666191011160543 · Cited by 34
Lactate accumulation induced by Akt2‐PDK1 signaling promotes pulmonary fibrosis
Sun, Z., Ji, Z., He, W., Duan, R., Qu, J., & Yu, G. (2024) · The FASEB Journal · doi:10.1096/fj.202302063rr · Cited by 34
Lung regeneration: diverse cell types and the therapeutic potential
Chen, Y., Li, Z., Ji, G., Wang, S., Mo, C., & Ding, B. (2024) · MedComm · doi:10.1002/mco2.494 · Cited by 35
Insights into the Role of Bioactive Food Ingredients and the Microbiome in Idiopathic Pulmonary Fibrosis
Mercader, J., Truyols-Vives, J., Río, C., López-Safont, N., Sala, E., & Chaplin, A. M. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176051 · Cited by 34
“IPF occurs primarily in older adults with a median survival of 2–3 years from diagnosis and, due to an increase in its incidence, it is becoming an economic burden on global health care [2].”
BackgroundInfluential
Therapeutic Effect of Neuraminidase-1–Selective Inhibition in Mouse Models of Bleomycin-Induced Pulmonary Inflammation and Fibrosis
Luzina, I. G., Lillehoj, E. P., Lockatell, V., Hyun, S. W., Lugkey, K. N., Imamura, A., Ishida, H., Cairo, C. W., Atamas, S. P., & Goldblum, S. E. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000223 · Cited by 35
Genomics of Human Fibrotic Diseases: Disordered Wound Healing Response
Stone, R. C., Chen, V., Burgess, J. L., Pannu, S., & Tomic‐Canic, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228590 · Cited by 35
“Advances in therapies have led to the development and approval of two drugs that slow the rate of fibrosis and associated functional decline in IPF: nintedanib, a tyrosine kinase inhibitor that targets growth factor signaling downstream of VEGFR, FGFR, and PDGFR; pirfenidone, which exerts anti-inflammatory as well as…”
Background
A nationwide population-based study of incidence and mortality of lung cancer in idiopathic pulmonary fibrosis
Song, M. J., Kim, S. Y., Park, M. S., Kang, M. J., Lee, S. H., & Park, S. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-82182-8 · Cited by 35
Home monitoring of physiology and symptoms to detect interstitial lung disease exacerbations and progression: a systematic review
Althobiani, M. A., Evans, R., Alqahtani, J. S., Aldhahir, A. M., Russell, A., Hurst, J. R., & Porter, J. C. (2021) · ERJ Open Research · doi:10.1183/23120541.00441-2021 · Cited by 35
Interrelation between extracellular vesicles miRNAs with chronic lung diseases
Dhar, R., Mukherjee, S., Mukerjee, N., Mukherjee, D., Devi, A., Ashraf, G. M., Alserihi, R. F., Tayeb, H. H., Hashem, A. M., Alexiou, A. T., et al. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30867 · Cited by 34
Mammalian Neuraminidases in Immune-Mediated Diseases: Mucins and Beyond
Lillehoj, E. P., Luzina, I. G., & Atamas, S. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.883079 · Cited by 35
Fibrosis pulmonar idiopática
León-Román, F., Valenzuela, C., & Molina‐Molina, M. (2022) · Medicina Clínica · doi:10.1016/j.medcli.2022.02.020 · Cited by 36
Albumin-based formononetin nanomedicines for lung injury and fibrosis therapy via blocking macrophage pyroptosis
Ouyang, B., Deng, L., Yang, F., Shi, H., Wang, N., Tang, W., Huang, X. X., Zhou, Y., Yu, H., Wei, Y., et al. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100643 · Cited by 37
Pathology of idiopathic pulmonary fibrosis with particular focus on vascular endothelium and epithelial injury and their therapeutic potential
Lu, W., Teoh, A. K. Y., Waters, M., Haug, G., Shakeel, I., Hassan, M. I., Shahzad, A. M., Larsson‐Callerfelt, A., Piccari, L., & Sohal, S. S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108757 · Cited by 35
DROSHA-Dependent AIM2 Inflammasome Activation Contributes to Lung Inflammation during Idiopathic Pulmonary Fibrosis
Cho, S. J., Hong, K. S., Jeong, J. H., Lee, M., Choi, A. M. K., Stout-Delgado, H. W., & Moon, J. (2019) · Cells · doi:10.3390/cells8080938 · Cited by 34
“It is characterized by focal areas of chronic inflammation, aberrant immune response, epithelial cell injury, proliferation of mesenchymal cells, and dysregulated wound healing, ultimately leading to progressive respiratory failure and death [3,4].”
Background
New Insights into the Implication of Mitochondrial Dysfunction in Tissue, Peripheral Blood Mononuclear Cells, and Platelets during Lung Diseases
Riou, M., Alfatni, A., Charles, A., Andrès, E., Pistea, C., Charloux, A., & Gény, B. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051253 · Cited by 34
Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials
Ji, H.-L., Liu, C., & Zhao, R. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i6.471 · Cited by 33
Ligustilide modulates oxidative stress, apoptosis, and immunity to avoid pathological damages in bleomycin induced pulmonary fibrosis rats via inactivating TLR4/MyD88/NF-KB P65
Luo, S., Gong, J., Cao, X., & Liu, S. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4233 · Cited by 33
Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital
Song, M. J., Moon, S. W., Choi, J. S., Lee, S. H., Lee, S. H., Chung, K. S., Jung, J. Y., Kang, Y. A., Park, M. S., Kim, Y. S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77837-x · Cited by 34
Associations of Monocyte Count and Other Immune Cell Types with Interstitial Lung Abnormalities
Kim, J. S., Axelsson, G. T., Moll, M. R., Anderson, M. R., Bernstein, E. J., Putman, R. K., Hida, T., Hatabu, H., Hoffman, E. A., Raghu, G., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202108-1967oc · Cited by 33
Self-citation
Cepharanthine Ameliorates Pulmonary Fibrosis by Inhibiting the NF-κB/NLRP3 Pathway, Fibroblast-to-Myofibroblast Transition and Inflammation
Chen, G., Li, J., Liu, H., Zhou, H., Liu, M., Liang, D., Meng, Z., Gan, H. K., Wu, Z., Zhu, X., et al. (2023) · Molecules · doi:10.3390/molecules28020753 · Cited by 32
Duvelisib attenuates bleomycin‐induced pulmonary fibrosis via inhibiting the PI 3 K /Akt/m TOR signalling pathway
Li, X., Ma, X., Miao, Y., Zhang, J., Xi, B., Li, W., Zhang, Q., Chen, L., Yang, Y., Li, H., et al. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17665 · Cited by 32
Single-Cell RNA Sequencing Provides New Insights into Therapeutic Roles of Thyroid Hormone in Idiopathic Pulmonary Fibrosis
Wang, L., Li, Z., Wan, R., Pan, X., Li, B., Zhao, H., Yang, J., Zhao, W., Wang, S., Wang, Q., et al. (2023) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2023-0080oc · Cited by 40
HSP47: A Therapeutic Target in Pulmonary Fibrosis
Sakamoto, N., Okuno, D., Tokito, T., Yura, H., Kido, T., Ishimoto, H., Tanaka, Y., & Mukae, H. (2023) · Biomedicines · doi:10.3390/biomedicines11092387 · Cited by 33
“The pathogenesis of fibrosis is characterized by the recurrent epithelial cell injury, senescent alveolar epithelial cells, and release of pro-fibrotic mediators, leading to the extracellular matrix (ECM) deposition by myofibroblasts [2].”
Background
Homeostatic chemokines as putative therapeutic targets in idiopathic pulmonary fibrosis
Russo, R. C., Quesniaux, V. F. J., & Ryffel, B. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.10.003 · Cited by 32
Phosphorylation of FOXN3 by NEK6 promotes pulmonary fibrosis through Smad signaling
Yu, J., Li, Y., Li, Y., Liu, X., Huo, Q., Wu, N., Zhang, Y., Zeng, T., Zhang, Y., Li, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56922-7 · Cited by 35
PARP1 stabilizes FOXN3 to suppress pulmonary fibrosis through p38-related feedback regulation
Zhu, X., Huo, Q., Jin, L., Du, J., Yu, J., Wang, H., Wu, N., Li, Y., Rui, Y., Zhao, C., et al. (2026) · Science Advances · doi:10.1126/sciadv.ady1681 · Cited by 33
Spectrum of interstitial lung disease in China from 2000 to 2012
Ban, C., Yan, W., Xie, B., Zhu, M., Liu, Y., Zhang, S., Ye, Q., Ren, Y., Jiang, D., Geng, J., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.01554-2017 · Cited by 32
“Published on August 2, 2018 as doi: 10.1183/13993003.01554-2017ERJ Express Copyright 2018 by the European Respiratory Society.”
BackgroundInfluential
LOXL2, a copper-dependent monoamine oxidase, activates lung fibroblasts through the TGF-β/Smad pathway
Wen, X., Liu, Y., Bai, Y. Z., Li, M., Fu, Q., & Zheng, Y. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3927 · Cited by 32
Assessing Patterns of Palliative Care Referral and Location of Death in Patients with Idiopathic Pulmonary Fibrosis: A Sixteen-Year Single-Center Retrospective Cohort Study
Zou, R. H., Nouraie, M. S., Chen, X., Saul, M. I., Kaminski, N., Gibson, K. F., Kass, D. J., & Lindell, K. O. (2019) · Journal of Palliative Medicine · doi:10.1089/jpm.2018.0400 · Cited by 33
Practical approach to establishing pulmonary rehabilitation for people with non‐COPD diagnoses
Granger, C. L., Morris, N. R., & Holland, A. E. (2019) · Respirology · doi:10.1111/resp.13562 · Cited by 32
LncRNA PFAR contributes to fibrogenesis in lung fibroblasts through competitively binding to miR-15a
Sun, J., Su, W., Zhao, X., Shan, T., Jin, T., Guo, Y., Li, C. R., Li, R., Zhou, Y., Shan, H., et al. (2019) · Bioscience Reports · doi:10.1042/bsr20190280 · Cited by 32
Pulmonary Fibrosis in Children
Nathan, N., Siléo, C., Thouvenin, G., Berdah, L., Delestrain, C., Manali, E., Papiris, S. A., Léger, P., Pointe, H. D. L., L’Herminé, A. C., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091312 · Cited by 32
Therapeutic targeting of 15-PGDH in murine pulmonary fibrosis
Smith, J. N. P., Witkin, M. D., Jogasuria, A. P., Christo, K. F., Raffay, T. M., Markowitz, S. D., & Desai, A. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-68336-0 · Cited by 32
Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Beck, H., Thaler, T., Meibom, D., Meininghaus, M., Jörißen, H., Dietz, L., Terjung, C., Bairlein, M., von Bühler, C.-J., Anlauf, S., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00834 · Cited by 33
Longitudinal micro-computed tomography-derived biomarkers quantify non-resolving lung fibrosis in a silicosis mouse model
Dekoster, K., Decaesteker, T., Berghen, N., Broucke, S. V. D., Jonckheere, A., Wouters, J., Krouglov, A., Lories, R. J. U., Langhe, E. D., Hoet, P., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73056-6 · Cited by 34
The Impact of the Envisia Genomic Classifier in the Diagnosis and Management of Patients with Idiopathic Pulmonary Fibrosis
Lasky, J. A., Case, A., Unterman, A., Kreuter, M., Scholand, M. B., Chaudhary, S., Lofaro, L. R., Johnson, M., Huang, J., Bhorade, S. M., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202107-897oc · Cited by 32
Complement protein C1q activates lung fibroblasts and exacerbates silica-induced pulmonary fibrosis in mice
Ogawa, T., Shichino, S., Ueha, S., Ogawa, S., & Matsushima, K. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.02.090 · Cited by 30
Physiological Effects of Ferroptosis on Organ Fibrosis
Du, X., Dong, R., Wu, Y., & Ni, B. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5295434 · Cited by 33
Endothelin-1 as a Biomarker of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Associated with Autoimmune Diseases
Pulito‐Cueto, V., Genre, F., López‐Mejías, R., Cuesta, V. M. M., Fernandez, D. I., Portilla, V., Mora-Gil, M. S., Ocejo-Vinyals, J. G., Gualillo, O., Blanco, R., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021275 · Cited by 32
“However, its diagnosis is often difficult and delayed, constituting a significant concern for clinicians [1,2].”
Background
Molecular and Genetic Biomarkers in Idiopathic Pulmonary Fibrosis: Where Are We Now?
Tomos, I. P., Roussis, I., Matthaiou, A. Μ., & Dimakou, K. (2023) · Biomedicines · doi:10.3390/biomedicines11102796 · Cited by 35
“A repetitive alveolar epithelial injury in genetically susceptible individuals is considered responsible for the activation of an aberrant wound-healing process, excessive production of pro-ﬁbrotic mediators, activation of ﬁbroblasts and accumulation of the extracellular matrix (ECM) [8–12].”
BackgroundInfluential
The gut-lung axis: Gut microbiota changes associated with pulmonary fibrosis in mouse models induced by bleomycin
Quan, Y., Yin, Z., Chen, S., Lang, J., Han, L., Yi, J., Zhang, L., Yue, Q., Tian, W., Chen, P., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.985223 · Cited by 32
Modeling fibrotic alveolar transitional cells with pluripotent stem cell-derived alveolar organoids
Ptasinski, V., Monkley, S. J., Öst, K., Tammia, M., Alsafadi, H. N., Overed-Sayer, C. L., Hazon, P., Wagner, D. E., & Murray, L. A. (2023) · Life Science Alliance · doi:10.26508/lsa.202201853 · Cited by 34
Targeting iron-metabolism:a potential therapeutic strategy for pulmonary fibrosis
Sun, Y., Ren, Y., Song, L., Wang, Y.-Y., Li, T., Wu, Y., Li, L., & Yang, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116270 · Cited by 32
Hypoxia-inducible factor 2 regulates alveolar regeneration after repetitive injury in three-dimensional cellular and in vivo models
McCall, A. S., Gutor, S. S., Tanjore, H., Burman, A., Sherrill, T. P., Chapman, M., Calvi, C. L., Han, D., Camarata, J. E., Hunt, R. P., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adk8623 · Cited by 35
Mitogen-activated Protein Kinase–activated Protein Kinase 2 Inhibition Attenuates Fibroblast Invasion and Severe Lung Fibrosis
Liang, J., Liu, N., Liu, X., Mena, J. M., Xie, T., Geng, Y., Huan, C., Zhang, Y., Taghavifar, F., Huang, G., et al. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0033oc · Cited by 32
Clinical significance of serum S100 calcium‐binding protein A4 in idiopathic pulmonary fibrosis
Akiyama, N., Hozumi, H., Isayama, T., Okada, J., Sugiura, K., Yasui, H., Suzuki, Y., Kono, M., Karayama, M., Furuhashi, K., et al. (2019) · Respirology · doi:10.1111/resp.13707 · Cited by 30
Human Fibrosis: Is There Evidence for a Genetic Predisposition in Musculoskeletal Tissues?
Dagneaux, L., Owen, A. R., Bettencourt, J. W., Barlow, J. D., Amadio, P. C., Kocher, J. P. A., Morrey, M. E., Sánchez‐Sotelo, J., Berry, D. J., van Wijnen, A. J., et al. (2020) · The Journal of Arthroplasty · doi:10.1016/j.arth.2020.05.070 · Cited by 31
Inula japonica ameliorated bleomycin-induced pulmonary fibrosis via inhibiting soluble epoxide hydrolase
Zhao, W., Luan, Z., Liu, T., Ming, W., Huo, X., Huang, H., Sun, C., Zhang, B., & Ma, X. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104065 · Cited by 31
Club cell-specific role of programmed cell death 5 in pulmonary fibrosis
Park, S., Hong, J. Y., Lee, S. Y., Lee, S., Kim, M. J., Kim, S. Y., Kim, K. W., Shim, H. S., Park, M. S., Lee, C. G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23277-8 · Cited by 31
Dissecting the Role of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis: Cause or Solution
Samarelli, A. V., Tonelli, R., Heijink, I. H., Medina, A. M., Marchioni, A., Bruzzi, G., Castaniere, I., Andrisani, D., Gozzi, F., Manicardi, L., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.692551 · Cited by 34
WNT Signalling in Lung Physiology and Pathology
Hu, Y., Ciminieri, C., Hu, Q., Lehmann, M., Königshoff, M., & Gosens, R. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_521 · Cited by 31
Determinants of survival after lung transplantation in telomerase-related gene mutation carriers: A retrospective cohort
Phillips-Houlbracq, M., Mal, H., Cottin, V., Gauvain, C., Beier, F., de Fontbrune, F. S., Sidali, S., Mornex, J., Hirschi, S., Roux, A., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16893 · Cited by 34
Complex Involvement of the Extracellular Matrix, Immune Effect, and Lipid Metabolism in the Development of Idiopathic Pulmonary Fibrosis
Qian, W., Xia, S., Yang, X., Yu, J., Guo, B., Lin, Z., Wei, R., Mao, M., Zhang, Z., Zhao, G., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.800747 · Cited by 31
“Effective treatment is largely confined to lung transplantation, but this is limited by donor availability and transplantation complications (Mushiroda et al., 2008; Lederer and Martinez, 2018; Raghu et al., 2018).”
Background
High complement protein C1q levels in pulmonary fibrosis and non-small cell lung cancer associated with poor prognosis
Kou, W., Li, B., Shi, Y., Zhao, Y., Yu, Q., Zhuang, J., Xu, Y., & Peng, W. (2022) · BMC Cancer · doi:10.1186/s12885-021-08912-3 · Cited by 30
Serum creatinine/cystatin C ratio is a surrogate marker for sarcopenia in patients with idiopathic pulmonary fibrosis
Fujita, K., Ohkubo, H., Nakano, A., Takeda, N., Fukumitsu, K., Fukuda, S., Kanemitsu, Y., Uemura, T., Tajiri, T., Maeno, K., et al. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02000-3 · Cited by 33
Rare surfactant‐related variants in familial and sporadic pulmonary fibrosis
Sutton, R. M., Bittar, H. E. T., Sullivan, D. I., Silva, A. G., Bahudhanapati, H., Parikh, A. H., Zhang, Y., Gibson, K. F., McDyer, J. F., Kass, D. J., et al. (2022) · Human Mutation · doi:10.1002/humu.24476 · Cited by 33
Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records
Onishchenko, D., Marlowe, R. J., Ngufor, C. G., Faust, L. J., LIMPER, A. H., Hunninghake, G. M., Martínez, F. J., & Chattopadhyay, I. (2022) · Nature Medicine · doi:10.1038/s41591-022-02010-y · Cited by 34
Tanshinone IIA Regulates Keap1/Nrf2 Signal Pathway by Activating Sestrin2 to Restrain Pulmonary Fibrosis
Li, H., Wu, M., Guo, C., Zhai, R., & Chen, J. (2022) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x22500914 · Cited by 34
Clinical characteristics and outcomes of hypersensitivity pneumonitis
Wang, L., Cai, H., Xiao, Y., Wang, Y., & Cao, M. (2019) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000256 · Cited by 31
A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review
Man, R. K., Gogikar, A., Nanda, A., Janga, L. S. N., Sambe, H. G., Yasir, M., & Ramphall, S. (2024) · Cureus · doi:10.7759/cureus.54268 · Cited by 30
Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Strykowski, R. K., & Adegunsoye, A. (2023) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2023.01.010 · Cited by 30
A systematic review of the research progress of traditional Chinese medicine against pulmonary fibrosis: from a pharmacological perspective
Qin, S., Tan, P., Xie, J., Zhou, Y., & Zhao, J. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00797-7 · Cited by 34
Horizontal transmission of gut microbiota attenuates mortality in lung fibrosis
Gurczynski, S. J., Lipinski, J. H., Strauss, J., Alam, S., Huffnagle, G. B., Ranjan, P., Kennedy, L. H., Moore, B. B., & O’Dwyer, D. N. (2023) · JCI Insight · doi:10.1172/jci.insight.164572 · Cited by 32
Commensal Oral Microbiota, Disease Severity, and Mortality in Fibrotic Lung Disease
O’Dwyer, D. N., Kim, J. S., Ma, S., Ranjan, P., Das, P., Lipinski, J. H., Metcalf, J. D., Falkowski, N. R., Yow, E. S., Anstrom, K. J., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202308-1357oc · Cited by 33
Unraveling the interplay between vital organelle stress and oxidative stress in idiopathic pulmonary fibrosis
Mohanan, A., Washimkar, K. R., & Mugale, M. N. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119676 · Cited by 30
Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
Valenzuela, C., Torrisi, S. E., Kahn, N. C., Quaresma, M., Stowasser, S., & Kreuter, M. (2020) · Respiratory Research · doi:10.1186/s12931-019-1269-6 · Cited by 29
Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
Snyder, L. D., Mosher, C. L., Holtze, C. H., LANCASTER, L. H., Flaherty, K. R., Noth, I., Neely, M. L., Hellkamp, A. S., Bender, S. D., Conoscenti, C., et al. (2020) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2020-000567 · Cited by 33
Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host Mediators
O’Hare, M., Amarnani, D., Whitmore, H. A. B., An, M. B., Mariño, C., Ramos, L., Delgado‐Tirado, S., Hu, X., Chmielewska, N., Chandrahas, A. S., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.04.006 · Cited by 31
Associations Between Diabetes and Idiopathic Pulmonary Fibrosis: a Study-level Pooled Analysis of 26 Million People
Li, C., Xiao, Y., Hu, J., Hu, Z., Yan, J., Zhou, Z., & Mei, Z. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab553 · Cited by 30
Nano-designed CO donor ameliorates bleomycin-induced pulmonary fibrosis via macrophage manipulation
Guo, C., Zhang, C., Xia, Z., Song, B., Hu, W., Cui, Y., Xue, Y., Xia, M., Xu, D., Zhang, S., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.047 · Cited by 30
Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials
Wu, W., Qiu, L., Wu, J., Liu, X., & Zhang, G. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-050004 · Cited by 30
Basal Cell–derived WNT7A Promotes Fibrogenesis at the Fibrotic Niche in Idiopathic Pulmonary Fibrosis
Huang, G., Liang, J., Huang, K. Y., Liu, X., Taghavifar, F., Yao, C., Parimon, T., Liu, N., Dai, K., Aziz, A. W., et al. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0074oc · Cited by 31
Therapeutic strategies targeting pro-fibrotic macrophages in interstitial lung disease
Isshiki, T., Vierhout, M., Naiel, S., Ali, P., Yazdanshenas, P., Kumaran, V. R., Yang, Z., Dvorkin‐Gheva, A., Rullo, A. F., Kolb, M. R. J., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115501 · Cited by 32
Pulmonary Delivery of Specialized Pro-Resolving Mediators-Based Nanotherapeutics Attenuates Pulmonary Fibrosis in Preclinical Animal Models
Li, J., Xiao, Y., Zhang, Y., Li, S., Zhao, M., Xia, T., & Meng, H. (2023) · ACS Nano · doi:10.1021/acsnano.2c10388 · Cited by 30
The Chemokine System as a Key Regulator of Pulmonary Fibrosis: Converging Pathways in Human Idiopathic Pulmonary Fibrosis (IPF) and the Bleomycin-Induced Lung Fibrosis Model in Mice
Russo, R. C., & Ryffel, B. (2024) · Cells · doi:10.3390/cells13242058 · Cited by 35
“With approximately 30 cases per 100,000 people and around 34,000 new cases annually in the United States [74,82,83], IPF has a high mortality rate due to a gradual decline in lung function, resulting in respiratory failure, with an average survival of 3 to 5 years after diagnosis [74,78,79,82].”
Influential
Roles of gut microbiome-associated metabolites in pulmonary fibrosis by integrated analysis
Li, J., Wu, W., Kong, X., Yang, X., Li, K., Jiang, Z., Zhang, C., Zou, J., & Liang, Y. (2024) · npj Biofilms and Microbiomes · doi:10.1038/s41522-024-00631-4 · Cited by 35
2018 Clinical Practice Guideline Summary for Clinicians: Diagnosis of Idiopathic Pulmonary Fibrosis
Thomson, C. C., Duggal, A., Bice, T. J., Lederer, D. J., Wilson, K. C., & Raghu, G. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201809-604cme · Cited by 30
Self-citation
Morphological and molecular motifs of fibrosing pulmonary injury patterns
Jonigk, D. D., Stark, H., Braubach, P., Neubert, L., Shin, H., Izykowski, N., Welte, T., Janciauskiene, S. M., Warnecke, G., Haverich, A., et al. (2019) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.141 · Cited by 28
“J Pathol Clin Res; October 2019; 5: 256–271 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations ar…”
Influential
Associations of Serum Adipokines With Subclinical Interstitial Lung Disease Among Community-Dwelling Adults
Kim, J. S., Anderson, M. R., Podolanczuk, A. J., Kawut, S. M., Allison, M., Raghu, G., Stukovsky, K. H., Hoffman, E. A., Tracy, R. P., Barr, R. G., et al. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.10.011 · Cited by 29
Self-citation
The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis
Nathan, S. D., Brown, A. W., Moğulkoç, N., Soares, F. D. S. N., Collins, A., Cheng, J. M., Peterson, J., Cannon, B., King, C. S., & Barnett, S. D. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.106068 · Cited by 28
Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
Chaudhary, S., Natt, B., Bime, C., Knox, K. S., & Glassberg, M. K. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00539 · Cited by 31
“IPF is progressive and eventually fatal in most patients (39).”
Background
Endothelial Colony-Forming Cells from Idiopathic Pulmonary Fibrosis Patients Have a High Procoagulant Potential
Billoir, P., Blandinières, A., Gendron, N., Chocron, R., Günther, S., Philippe, A., Guérin, C. L., Israël‐Biet, D., & Smadja, D. M. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10043-4 · Cited by 32
An efficient electrochemical assay for miR-3675-3p in human serum based on the nanohybrid of functionalized fullerene and metal-organic framework
Zuo, J., Yuan, Y., Zhao, M., Wang, J., Chen, Y., Zhu, Q., & Bai, L. (2020) · Analytica Chimica Acta · doi:10.1016/j.aca.2020.10.017 · Cited by 29
Regorafenib-Attenuated, Bleomycin-Induced Pulmonary Fibrosis by Inhibiting the TGF-β1 Signaling Pathway
Li, X., Ma, L., Huang, K., Wei, Y., Long, S., Liu, Q., Zhang, D., Wu, S., Wang, W., Yang, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041985 · Cited by 30
Calycosin attenuates pulmonary fibrosis by the epithelial-mesenchymal transition repression upon inhibiting the AKT/GSK3β/β-catenin signaling pathway
Liu, X., Shao, Y., Zhang, X., Ji, X., Xie, M., & Liu, H. (2021) · Acta Histochemica · doi:10.1016/j.acthis.2021.151746 · Cited by 29
Latent Transforming Growth Factor-β Binding Protein-2 Regulates Lung Fibroblast-to-Myofibroblast Differentiation in Pulmonary Fibrosis via NF-κB Signaling
Zou, M., Zou, J., Hu, X., Zheng, W., Zhang, M., & Cheng, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.788714 · Cited by 33
Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis: Part A
Wiertz, I. A., Moll, S. A., Seeliger, B., Barlo, N. P., van der Vis, J. J., Korthagen, N. M., Rijkers, G. T., Ruven, H. J. T., Grutters, J. C., Prasse, A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061940 · Cited by 29
Recommendations of scRNA-seq Differential Gene Expression Analysis Based on Comprehensive Benchmarking
Gagnon, J., Pi, L., Ryals, M. M., Wan, Q., Hu, W., Ouyang, Z., Zhang, B., & Li, K. (2022) · Life · doi:10.3390/life12060850 · Cited by 31
Epithelial senescence in idiopathic pulmonary fibrosis is propagated by small extracellular vesicles
Asghar, S., Monkley, S. J., Smith, D. J. F., Hewitt, R. J., Grime, K., Murray, L. A., Overed-Sayer, C. L., & Molyneaux, P. L. (2023) · Respiratory Research · doi:10.1186/s12931-023-02333-5 · Cited by 29
Exploring computer-based imaging analysis in interstitial lung disease: opportunities and challenges
Felder, F., & Walsh, S. L. F. (2023) · ERJ Open Research · doi:10.1183/23120541.00145-2023 · Cited by 31
Spatially distinct molecular patterns of gene expression in idiopathic pulmonary fibrosis
Blumhagen, R. Z., Kurche, J. S., Cool, C. D., Walts, A. D., Heinz, D. E., Fingerlin, T. E., Yang, I. V., & Schwartz, D. A. (2023) · Respiratory Research · doi:10.1186/s12931-023-02572-6 · Cited by 31
Blockade of TREM2 ameliorates pulmonary inflammation and fibrosis by modulating sphingolipid metabolism
Gu, X., Kang, H., Cao, S., Tong, Z., & Song, N. (2025) · Translational Research · doi:10.1016/j.trsl.2024.10.002 · Cited by 28
Low‐dose administration of bleomycin leads to early alterations in lung mechanics
Headley, L., Bi, W., Wilson, C., Collum, S. D., Chavez, M., Darwiche, T., Mertens, T. C. J., Hernandez, A. M., Siddiqui, S. R., Rosenbaum, S., et al. (2018) · Experimental Physiology · doi:10.1113/ep087322 · Cited by 27
DROSHA-Dependent miRNA and AIM2 Inflammasome Activation in Idiopathic Pulmonary Fibrosis
Cho, S. J., Lee, M., Stout-Delgado, H. W., & Moon, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051668 · Cited by 28
“IPF has been linked to certain areas of chronic inflammation, abnormal immune responses, cell injury, cell proliferation, and impaired wound healing, which leads to respiratory failure and death [3,4].”
Background

Authors: Lederer, D. J., & Martinez, F. J.
Affiliations: Columbia University Irving Medical Center (US)
From the Departments of Medicine and Epidemiology, Columbia University Irving Medical Center (D.J.L.), and the Department of Medicine, Weill Cornell Medical Center (F.J.M.) — both in New York.
ORCID: Lederer, David J.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2018-05-10
Volume: 378
Issue: 19
Pages: 1811-1823
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmra1705751
OpenAlex: W2799479598
Cited by: 2,056
References: 98
Citations by year: 2026: 248 · 2025: 267 · 2024: 299 · 2023: 308 · 2022: 301 · 2021: 266 · 2020: 197 · 2019: 129 · 2018: 40
FWCI: 28.43
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
Keywords: idiopathic pulmonary fibrosis, incidence, early recognition, supportive care, pharmacotherapy, disease progression, lung transplantation
MeSH terms: Diagnosis, Differential, Dyspnea, Enzyme Inhibitors, Humans, Indoles, Lung, Oxygen Inhalation Therapy, Prognosis, Pyridones, Risk Factors, Tomography, X-Ray Computed, Transforming Growth Factor beta, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Idiopathic Pulmonary Fibrosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks